Floatz logo

Autologous Cd19/Cd22 Dual-Target Car-T Module

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Beijing BiotechCell therapyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

140 Active assets in the Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Washington
Phase 3BBB
VINCRISTINE SULFATE
City of Hope Medical Center
Phase 3BB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
City of Hope Medical Center
Phase 3BB
MERCAPTOPURINE ANHYDROUS
SWOG Cancer Research Network
Phase 3BB
PEGASPARGASE
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Autologous Cd19/Cd22 Dual-Target Car-T Module is also rated in:

B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
47 / 100
View asset →
Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic NeoplasmDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →